# MLH1

## Overview
The MLH1 gene encodes the protein mutL homolog 1, a pivotal component of the DNA mismatch repair (MMR) system, which is essential for maintaining genomic stability by correcting replication errors. As a member of the GHKL ATPase/kinase superfamily, the MLH1 protein features a noncanonical ATPase domain crucial for its function. It forms a heterodimer with PMS2, known as the MutLα complex, which plays a central role in the MMR pathway by interacting with other proteins to excise and resynthesize mismatched DNA. Beyond its primary role in DNA repair, MLH1 is involved in genomic damage checkpoint signaling and has been implicated in mitochondrial function and cytoskeletal organization. Mutations in the MLH1 gene are associated with Lynch syndrome, a hereditary condition that increases the risk of colorectal and other cancers, highlighting its clinical significance in cancer predisposition (Prolla1994MLH1; Rashid2019MLH1; Wu2008Human).

## Structure
The MLH1 protein is a crucial component of the DNA mismatch repair (MMR) system, with a well-defined molecular structure. The protein's N-terminal domain (NTD) includes an ATPase domain, which is essential for its function in MMR. This domain features a noncanonical ATPase Bergerat fold, characteristic of the GHKL ATPase/kinase superfamily, and contains a conserved GFRGE(A/G)L motif crucial for nucleotide binding (Wu2015Structure). The NTD also includes a 'transducer' domain, connected to the ATPase domain by a two-helix linker (Wu2015Structure).

The MLH1 protein forms a crystallographic dimer, similar to the E. coli MutL-Mg-ADP complex, indicating a quaternary structure that facilitates its interaction with other proteins in the MMR pathway (Wu2015Structure). The C-terminal domain of MLH1 interacts with PMS1, contributing to the PMS1 endonuclease site, which is vital for its role in DNA repair (Gueneau2013Structure).

Post-translational modifications, such as phosphorylation, can regulate MLH1 activity, although specific details are not provided in the context. The protein may also exist in different splice variant isoforms, potentially affecting its structure and function.

## Function
The MLH1 gene encodes a protein that plays a critical role in the DNA mismatch repair (MMR) system, which is essential for maintaining genomic stability by correcting errors that occur during DNA replication. In healthy human cells, MLH1 forms a heterodimer with PMS2, known as the MutLα complex, which interacts with other MMR proteins to excise and resynthesize mismatched DNA (Prolla1994MLH1). This activity is crucial for preventing mutations that could lead to cancer.

MLH1 is also involved in genomic damage checkpoint signaling in response to DNA interstrand crosslinks (ICLs). It is not directly involved in the repair of these lesions but is essential for signaling pathways that activate cell cycle checkpoints and apoptosis. MLH1 facilitates the activation of proteins such as ATR, CHK1, and CHK2, which are crucial for the cellular response to DNA damage (Wu2008Human). 

Beyond its role in MMR, MLH1 has been implicated in mitochondrial function, where its deficiency is associated with reduced mitochondrial gene expression and increased reactive oxygen species, potentially contributing to tumorigenesis (Rashid2019MLH1). MLH1 also interacts with proteins involved in cytoskeletal organization, suggesting a broader role in cellular processes beyond DNA repair (Brieger2010Cytoskeletal).

## Clinical Significance
Mutations in the MLH1 gene are significantly associated with Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), a condition that predisposes individuals to colorectal and other types of cancer (Lucci-Cordisco2006The; Takahashi2007Functional). These mutations often result in microsatellite instability, a hallmark of Lynch syndrome-associated tumors, due to impaired DNA mismatch repair (Mahdouani2022Functional; Hinrichsen2013Expression). 

MLH1 mutations can include missense mutations, nonsense mutations, and large genomic rearrangements, all of which can disrupt normal protein function and stability (Renkonen2003Altered; Belvederesi2006Assessing). For instance, specific missense mutations such as P648S, L559R, and Y646C have been shown to impair the interaction of MLH1 with PMS2, another protein crucial for mismatch repair, leading to protein instability and loss of function (Belvederesi2006Assessing).

Alterations in MLH1 expression, such as promoter hypermethylation, can also lead to gene silencing, contributing to tumorigenesis in Lynch syndrome (Mahdouani2022Functional). These genetic and epigenetic changes underscore the critical role of MLH1 in maintaining genomic stability and its impact on cancer development.

## Interactions
MLH1 (mutL homolog 1) is a key component of the DNA mismatch repair (MMR) system and forms several important interactions with other proteins and nucleic acids. In humans, MLH1 interacts with hPMS2 to form the MutLα heterodimer, which is essential for MMR. This interaction is facilitated by the C-terminal domains of both proteins, which are crucial for the formation of the heterodimer (Kondo2001The; Cutalo2006Mapping). MLH1 also forms heterodimers with hMLH3 and hPMS1, competing with hPMS2 for binding to MLH1. These interactions occur at the C-terminal region of MLH1, specifically between residues 492 and 742 (Kondo2001The).

MLH1 is involved in forming a ternary complex with PMS1 and MSH2 during the initiation of MMR in yeast, suggesting a similar role in humans (Prolla1994MLH1). The protein also interacts with DNA, binding both single-stranded and double-stranded forms, which is crucial for its function in MMR. Mutations in MLH1 that reduce DNA binding, such as R273E and R274E, lead to impaired MMR and mutator phenotypes (Hall2003DNA). These interactions highlight MLH1's central role in maintaining genomic stability.


## References


[1. (Mahdouani2022Functional) Marwa Mahdouani, Slim Ben Ahmed, Fahmi Hmila, Henda Rais, Rihab Ben Sghaier, Hanene Saad, Mariem Ben Said, Saber Masmoudi, Dorra Hmida, Angela Brieger, Stefan Zeuzem, Ali Saad, Moez Gribaa, and Guido Plotz. Functional characterization of mlh1 missense variants unveils mechanisms of pathogenicity and clarifies role in cancer. PLOS ONE, 17(12):e0278283, December 2022. URL: http://dx.doi.org/10.1371/journal.pone.0278283, doi:10.1371/journal.pone.0278283. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0278283)

[2. (Kondo2001The) E. Kondo. The interacting domains of three mutl heterodimers in man: hmlh1 interacts with 36 homologous amino acid residues within hmlh3, hpms1 and hpms2. Nucleic Acids Research, 29(8):1695–1702, April 2001. URL: http://dx.doi.org/10.1093/nar/29.8.1695, doi:10.1093/nar/29.8.1695. This article has 90 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/29.8.1695)

[3. (Lucci-Cordisco2006The) Emanuela Lucci-Cordisco, Luigi Boccuto, Giovanni Neri, and Maurizio Genuardi. The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of mlh1 and msh2 unclassified variants in lynch syndrome. Cancer Biomarkers, 2(1–2):11–27, June 2006. URL: http://dx.doi.org/10.3233/cbm-2006-21-203, doi:10.3233/cbm-2006-21-203. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.3233/cbm-2006-21-203)

[4. (Cutalo2006Mapping) Jenny M. Cutalo, Thomas A. Darden, Thomas A. Kunkel, and Kenneth B. Tomer. Mapping the dimer interface in the c-terminal domains of the yeast mlh1−pms1 heterodimer. Biochemistry, 45(51):15458–15467, December 2006. URL: http://dx.doi.org/10.1021/bi061392a, doi:10.1021/bi061392a. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi061392a)

[5. (Renkonen2003Altered) Elise Renkonen, Yange Zhang, Hannes Lohi, Reijo Salovaara, Wael M. Abdel-Rahman, Mef Nilbert, Kristiina Aittomäki, Heikki J. Järvinen, Jukka-Pekka Mecklin, Annika Lindblom, and Päivi Peltomäki. Altered expression of mlh1, msh2, and msh6 in predisposition to hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology, 21(19):3629–3637, October 2003. URL: http://dx.doi.org/10.1200/JCO.2003.03.181, doi:10.1200/jco.2003.03.181. This article has 122 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1200/JCO.2003.03.181)

[6. (Rashid2019MLH1) Sukaina Rashid, Marta O. Freitas, Danilo Cucchi, Gemma Bridge, Zhi Yao, Laura Gay, Marc Williams, Jun Wang, Nirosha Suraweera, Andrew Silver, Stuart A. C. McDonald, Claude Chelala, Gyorgy Szabadkai, and Sarah A. Martin. Mlh1 deficiency leads to deregulated mitochondrial metabolism. Cell Death &amp; Disease, October 2019. URL: http://dx.doi.org/10.1038/s41419-019-2018-y, doi:10.1038/s41419-019-2018-y. This article has 31 citations.](https://doi.org/10.1038/s41419-019-2018-y)

[7. (Brieger2010Cytoskeletal) Angela Brieger, Boris Adryan, Fabian Wolpert, Sandra Passmann, Stefan Zeuzem, and Jörg Trojan. Cytoskeletal scaffolding proteins interact with lynch‐syndrome associated mismatch repair protein mlh1. PROTEOMICS, 10(18):3343–3355, September 2010. URL: http://dx.doi.org/10.1002/pmic.200900672, doi:10.1002/pmic.200900672. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/pmic.200900672)

[8. (Belvederesi2006Assessing) Laura Belvederesi, Francesca Bianchi, Cristian Loretelli, Daniela Gagliardini, Eva Galizia, Raffaella Bracci, Saverio Rosati, Italo Bearzi, Alessandra Viel, Riccardo Cellerino, and Emilio Porfiri. Assessing the pathogenicity of mlh1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features. European Journal of Human Genetics, 14(7):853–859, May 2006. URL: http://dx.doi.org/10.1038/sj.ejhg.5201628, doi:10.1038/sj.ejhg.5201628. This article has 39 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.ejhg.5201628)

[9. (Prolla1994MLH1) Tomas A. Prolla, Qishen Pang, Eric Alani, Richard D. Kolodner, and R. Michael Liskay. Mlh1, pms1, and msh2 interactions during the initiation of dna mismatch repair in yeast. Science, 265(5175):1091–1093, August 1994. URL: http://dx.doi.org/10.1126/science.8066446, doi:10.1126/science.8066446. This article has 213 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.8066446)

[10. (Wu2008Human) Qi Wu and Karen M. Vasquez. Human mlh1 protein participates in genomic damage checkpoint signaling in response to dna interstrand crosslinks, while msh2 functions in dna repair. PLoS Genetics, 4(9):e1000189, September 2008. URL: http://dx.doi.org/10.1371/journal.pgen.1000189, doi:10.1371/journal.pgen.1000189. This article has 47 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1000189)

[11. (Hall2003DNA) M. C. Hall. Dna binding by yeast mlh1 and pms1: implications for dna mismatch repair. Nucleic Acids Research, 31(8):2025–2034, April 2003. URL: http://dx.doi.org/10.1093/nar/gkg324, doi:10.1093/nar/gkg324. This article has 69 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkg324)

[12. (Takahashi2007Functional) Masanobu Takahashi, Hideki Shimodaira, Corinne Andreutti-Zaugg, Richard Iggo, Richard D. Kolodner, and Chikashi Ishioka. Functional analysis of human mlh1 variants using yeast and in vitro mismatch repair assays. Cancer Research, 67(10):4595–4604, May 2007. URL: http://dx.doi.org/10.1158/0008-5472.can-06-3509, doi:10.1158/0008-5472.can-06-3509. This article has 116 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-06-3509)

[13. (Wu2015Structure) Hong Wu, Hong Zeng, Robert Lam, Wolfram Tempel, Iain D. Kerr, and Jinrong Min. Structure of the human mlh1 n-terminus: implications for predisposition to lynch syndrome. Acta Crystallographica Section F Structural Biology Communications, 71(8):981–985, July 2015. URL: http://dx.doi.org/10.1107/s2053230x15010183, doi:10.1107/s2053230x15010183. This article has 24 citations.](https://doi.org/10.1107/s2053230x15010183)

[14. (Gueneau2013Structure) Emeric Gueneau, Claudine Dherin, Pierre Legrand, Carine Tellier-Lebegue, Bernard Gilquin, Pierre Bonnesoeur, Floriana Londino, Cathy Quemener, Marie-Hélene Le Du, Josan A Márquez, Mireille Moutiez, Muriel Gondry, Serge Boiteux, and Jean-Baptiste Charbonnier. Structure of the mutlα c-terminal domain reveals how mlh1 contributes to pms1 endonuclease site. Nature Structural &amp; Molecular Biology, 20(4):461–468, February 2013. URL: http://dx.doi.org/10.1038/nsmb.2511, doi:10.1038/nsmb.2511. This article has 123 citations.](https://doi.org/10.1038/nsmb.2511)

[15. (Hinrichsen2013Expression) Inga Hinrichsen, Angela Brieger, Jörg Trojan, Stefan Zeuzem, Mef Nilbert, and Guido Plotz. Expression defect size among unclassified mlh1 variants determines pathogenicity in lynch syndrome diagnosis. Clinical Cancer Research, 19(9):2432–2441, April 2013. URL: http://dx.doi.org/10.1158/1078-0432.ccr-12-3299, doi:10.1158/1078-0432.ccr-12-3299. This article has 38 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-12-3299)